Humanized Anti-IL-5 Antibody Therapy

Cell. 2016 Apr 21;165(3):509. doi: 10.1016/j.cell.2016.04.020.


Eosinophils are suppressed by a new class of drugs targeting Interleukin-5 (IL-5), an eosinophil growth, activation, and survival factor. Humanized anti-IL-5 antibodies are effective in treating asthma patients with the severe eosinophilic form of the disease and are the first new class of asthma drugs approved in 12 years.